Slide 1: Imprimis Pharmaceuticals
Imprimis Imprimis PHARMACEUTICALS One Patient. One Physician. One Pharmacist.
Slide 2: Safe Harbor
imprimis Safe Harbor This presentation contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are
Slide 3: How Our Business Works
How Our Business Works oe, + IDENTIFY — We work with pharmacists, physicians, universities and research institutions who are seeking to develop their drug formulation ideas. + EVALUATE - We acquire rights to their formulations and screen for commercial feasibility using our proprietary Asset Review
Slide 4: The Story of the Creation of Dropless Cataract Surgery
imprimis The Story of the Creation Of Dropless Cataract Surgery + Eye drops for cataract surgery patients are expensive, difficult to administer and many patients call doctors’ offices with questions + Aphysician has an idea: Eliminate the eye drop regimen altogether and instead administer an inject
Slide 5: The Story of the Creation of Dropless Cataract Surgery
The Story of the Creation Of Dropless Cataract Surgery + The pharmacist and physician believe this drug formulation can help the 2.5M+ cataract patients in the US annually * They contact Imprimis, who analyzes the opportunity using its proprietary ARM™ process, buys the rights to commercialize the d
Slide 6: Exclusive Strategic Relationship
Exclusive Strategic Relationship * Professional Compounding Centers of America (PCCA) is the largest compounding pharmacy organization in North America (4,000+ pharmacy members worldwide) * PCCA relationship gives Imprimis exclusive access to: * Proprietary and proven drug formulations and drug deli
Slide 7: Asset Review Methodology (ARM)
Imprimis Asset Review Methodology (ARM™’) =) SY ~ Asset Ready to Monetize
Slide 8: Three pathways to monetize our proprietary assets
OW co imprimis mam) C PHARMACEUTICALS Three pathways to monetize our proprietary assets: + FDA‘s 505(b)(2) is a more rapid and less costly regulated approval pathway + Out-license to our pharmacy network + Out-license a drug delivery technology to our partners for sale to the pharmacy community
Slide 9: Ophthalmology: TriMox and TriMox+Vanc Injectable Solutions
Ophthalmology* TriMox and TriMox+Vanc Injectable Solutions Competitive Advantage Potential for improved compliance and lower costs for patients; Potential for good surgical outcomes and more efficient operations for Surgeons Customers Cataract/Cornea, Retina, Glaucoma, and other sub-specialty Ophtha
Slide 10: Ophthalmology: Lyophilized Epinephrine/Phenylephrine + Lidocaine (Shugarcaine)
Competitive Advantage Customers Estimated Market Size Commercialization Status Ophthalmology* Lyophilized Epinephrine/Phenylephrine + Lidocaine (Shugarcaine) The only preservative-free, sulfite-free mydriatic solution; Epinepherine causes pupil dilation; prevents Intraoperative Floppy-Iris Syndrome
Slide 11: Wound Management
Wound Management Tranexamic Acid + Bacitracin Competitive Advantage Rapid wound closure could reduce post dialysis time significantly; Potential for improved patient care and more efficient operations for dialysis centers Customers Commercial dialysis centers Estimated Market Size $150-$200 million?
Slide 12: Urology
Urology Injectable Pentoxifylline Solution Competitive Advantage Anti-fibrotic treatment; Potential for significant cost advantage over current treatments; Potential reduction in bruising and penile rupture adverse events Customers Patients suffering Peyronie’s Disease Estimated Market Size $500 mil
Slide 13: Impracor Pain Management
Impracor™ Competitive Advantage Customers Estimated Market Size Commercialization Status Pain Management Currently, no approved localized pain treatment for patients who are contraindicated for oral NSAIDs Renal compromised patients suffering from joint pain due to arthritis, personal injury or infl
Slide 14: Management Team
Management Team Dr. Victor Repkin IP Analyst Gary Seelhorst VP, Corporate Development Andrew R. Boll VP, Accounting Jeannette Filippone General Counsel Kassie Constantine Clinical Development Manager
Slide 15: Twelve-Month Execution Strategy
Twelve-Month Execution Strategy / © + Launch ophthalmic division in 1H 2014 2014 + Commercialize two ophthalmic formulations (TriMoxVanc and ve Shugarcaine) | + Ophthalmic division positive cash flow in Q4 2014 + Complete supportive clinical studies for all categories [ + Subject to the outcome of p
Slide 16: Capital Structure
Capital Structure : Number of Shares] _ Number of Number of | Number of Shares te Cha Cp at Stock Price of | Shares at $10 | Shares at $20 |Fully Diluted at $30 SA Ca At ela $4.50 Stock Price | Stock Price Stock Price Total Common Shares 8,970,364 8,961,583 8,961,583 3.961.583 | Total Options - Weig
Slide 17: Question & Answer
Question & Answer Mark L. Baum, C.E.O. mark@imprimispharma.com Imprimis Pharmaceuticals, Inc. 12626 High Bluff Drive, Suite 150 San Diego, California 92130 Tel: 858-704-4040 see @ee: Fax: 858-345-1745 | mM rl mM | S www.imprimispharma.com PHARMACEUTICALS
Slide 18: Imprimis Pharmaceuticals
Imprimis Imprimis PHARMACEUTICALS One Patient. One Physician. One Pharmacist.